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Serologic  
Screening for  
Neospora caninum, 
France
To the Editor: In the June 2008 
issue of Emerging Infectious Diseas-
es, McCann et al. (1) reported on sero-
logic screening for Neospora caninum 
antibodies and reported a lack of sero-
logic evidence for Neospora infection 
in humans in England, where preva-
lence of infection with the closely re-
lated parasite Toxoplasma gondii also 
is low. Only limited data are available 
on human exposure to Neospora. We 
investigated the seroprevalence of N. 
caninum in humans in France, where 
Toxoplasma  spp.  seroprevalence  is 
high.
Our study comprised 500 serum 
samples  from  healthy  women,  fol-
lowed at the Cochin–Port Royal Uni-
versity  Hospital  in  1997  within  the 
framework of toxoplasmosis surveil-
lance during pregnancy, and 400 serum 
samples  from  HIV-infected  patients. 
All serum samples were submitted to 
anti-Toxoplasma  antibody  testing  by 
using  indirect  immunofluorescence 
(IIF;  Toxo-spot  IFI;  bioMérieux, 
Marcy  l’Etoile,  France)  and  ELISA 
(Platelia Toxo IgG and IgM; BioRad, 
Hercules, CA, USA). An in-house mi-
croplate IIF test previously validated 
in  cattle  was  used  for  simultaneous 
detection of anti-Neospora and anti-
Toxoplasma  immunoglobulin  (Ig)  G 
on the same microplate. All samples 
were screened at dilutions of 1:20 and 
1:80, as is usually done in anti-Toxo-
plasma IIF assays in humans. Corre-
lation  between  the  anti-Toxoplasma 
IIF commercial test and in-house IIF 
was  excellent  (kappa  coefficient  = 
0.98) and allowed us to compare the 
antibody titers against both parasites. 
Forty  (8%)  samples  from  immuno-
competent persons and 21 (4%) from 
immunocompromised persons yielded 
a  weak  fluorescence  when  diluted 
1:20. All but 4 had significant titers of 
anti-Toxoplasma IgG (>200 IU/mL in 
77%  of  cases),  which  suggests  low-
level  cross-reactions.  Whereas  titers 
of >200 and >320 are considered suf-
ficient to diagnose neosporosis in dogs 
and cattle, respectively (2), positivity 
threshold was difficult to resolve in the 
absence of a positive human control. 
We decided on a positivity threshold 
of 1:80, which is similar to the thresh-
old defined by others in further studies 
using  an  indirect  fluorescence  anti-
body test in humans (3,4). None of the 
500 samples from immunocompetent 
persons  were  positive  for  Neospora 
antibodies when assessed at a dilution 
of 1:80. Within the group of immuno-
compromised persons, 3 were positive 
for Neospora antibodies at a titer of 
80, and 1 was positive at a titer of 160. 
Three of these 4 HIV-infected patients 
had high titers of anti-Toxoplasma IgG 
(>2,000 IU/mL), suggesting Toxoplas-
ma  serologic reactivation. We found 
no evidence of Neospora infection or 
exposure  in  immunocompetent  per-
sons  but  could  not  exclude  possible 
Neospora  infection  associated  with 
Toxoplasma  infection  or  reactivation 
in immunocompromised persons.
Taken  together,  our  data  agree 
with data from other studies conduct-
ed in European countries (1,5), which 
suggest  that  neosporosis  in  healthy 
humans  is  unlikely.  However,  the 
Neospora spp. seropositivity of some 
HIV-infected patients, although weak 
compared with the level of seroposi-
tivity in cattle or dogs, could suggest 
circulation of the parasite within im-
munocompromised  hosts,  a  hypoth-
esis  supported  by  Lobato  et  al.  (3). 
However, our observation of a strong 
serologic reactivation against T. gondii 
in 3 of 4 patients with anti-Neospora 
titers  >80  mostly  favors  cross-reac-
tivity involving homologous antigens 
of both parasites and nonspecific an-
tibody binding from polyclonal stimu-
lation of the immune system. Finally, 
one should keep in mind that the posi-
tive predictive value of a serologic test 
used  in  screening  in  low-prevalence 
populations is low. Large-scale stud-
ies are needed to more precisely deter-
mine the potential role of this parasite 
in  immunodeficient  humans  and  to 
isolate the parasite or detect Neospora 
DNA in such patients.
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Escherichia coli 
and Klebsiella 
pneumoniae  
Carbapenemase  
in Long-term Care 
Facility, Illinois, USA
To the Editor: Escherichia coli 
harboring Klebsiella pneumoniae car-
bapenemases (KPCs) are now rarely 
being reported. Worldwide, KPC-2 has 
been detected in Israel and the People’s 
Republic  of  China  (1,2).  Within  the 
United States, carbapenem-resistant E. 
coli carrying blaKPC has been isolated 
in New Jersey (3) and Cleveland, Ohio 
(4), and 7 carbapenem-resistant E. coli 
isolates were obtained from 3 differ-
ent hospitals in Brooklyn, New York 
(5). Urban et al. (6) recently reported 
9 KPC-2 and KPC-3 carbapenemases 
in urinary E. coli isolates from 7 long-
term care facilities. We report such an 
isolate from a resident of a long-term 
care facility.
This case involved a 68-year-old 
female  resident  of  a  long-term  care 
facility in Centralia, Illinois, who had 
multiple  chronic  medical  problems, 
including  cerebral  palsy,  a  seizure 
disorder,  and  recurrent  urinary  tract 
infections. A urine culture grew >105 
CFU/mL of E. coli susceptible to ami-
kacin,  gentamicin,  tobramycin,  pip-
eracillin/tazobactam,  trimethoprim/
sulfamethoxazole, imipenem, and ni-
trofurantoin.  Tigecycline  susceptibil-
ity was not determined. Trimethoprim/
sulfamethoxazole  therapy  was  initi-
ated. Follow-up urine culture almost 
3 weeks later again grew >105 CFU/
mL of E. coli, now susceptible to ami-
kacin, gentamicin, tobramycin, nitro-
furantoin, and tigecycline. The isolate 
was resistant to imipenem and mero-
penem. A modified Hodge test demon-
strated production of a carbapenemase 
(7), and the blaKPC gene was detected 
by  PCR  at  the  Centers  for  Disease 
Control  and  Prevention  (CDC).  The 
patient  was  treated  with  a  10-day 
course  of  nitrofurantoin,  100  mg  by 
gastrostomy  tube  2×  per  day.  Chart 
review indicated that contact precau-
tions were instituted only after discov-
ery of the second E. coli isolate.
Seventeen  days  later,  a  repeat 
urine culture grew >105 CFU/mL of K. 
pneumoniae susceptible only to ami-
kacin,  gentamicin,  tobramycin,  and 
tigecycline. No treatment was given. 
Follow-up  urine  culture  grew  >105 
CFU/mL of K. pneumoniae again with 
a similar resistance pattern. The modi-
fied Hodge test result was positive (7) 
and was confirmed as blaKPC positive 
by  PCR  at  CDC.  The  resident  was 
transferred to an acute care facility for 
further evaluation and was treated with 
amikacin. At completion of therapy, a 
repeat urine culture was negative for 
organisms.
Our case, like that of Urban et al. 
(6), involved a urinary isolate from a 
resident of a long-term care facility. 
As  increasing  numbers  of  resistant 
gram-negative  rods  colonize  such 
patients,  the  patients  may  acquire  a 
bacterium  carrying  a  KPC  plasmid 
conferring broad-spectrum resistance 
as described in our patient. These plas-
mids may then be laterally transferred 
to  other  gram-negatives,  which  may 
have occurred in this case.
Our case underscores the gravity 
of the evolutionary process of emer-
gent,  multidrug–resistant  enterobac-
teriaceae. Even though E. coli strains 
that harbor carbapenemase genes are 
not ubiquitous, additional therapeutic 
interventions  are  needed  to  prevent 
the spread of these bacteria, which are 
likely to infect increasing numbers of 
patients.
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